Series A Deal Volume And Money Up In H1
This article was originally published in Start Up
Biopharma, medtech and diagnostics start-ups raised a whopping 51% more Series A money in the first half of 2015 than during the same period last year, and the number of deals was way up too.
You may also be interested in...
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
The partnership between GSK and Avalon has now launched six new biotechs in just over two years, each housed at Avalon’s incubator space in San Diego.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.